Clinical Trials · NCT01427387
A Study to Evaluate Safety of Multiple Dose of ASP0456 in Healthy Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Astellas Pharma Inc
- Enrollment
- 44
- Start date
- Jun 2011
- Locations
- 1 site, Japan
- Primary endpoint
- Pharmacokinetics (such as Cmax, AUC and t1/2 etc.) of ASP0456 assessed by its plasma concentration change